Scientific studies, and news coverage about them, often declare that a study “controlled” for certain variables. For example, ...
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing ...
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the ...
SHIELD Phase 2 Study: first payment made under the clinical trial agreement with Mount Sinai and study drug ordered; ...
The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active ...
Ascletis Pharma Inc. announced positive results from a randomized, double-blind, placebo-controlled 28-day proof-of-concept clinical trial with ASC50 in mild-to-moderate plaque psoriasis patients in ...
For years, marijuana has been promoted as a home remedy for relaxation and stress relief. But now, new research confirms that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results